EU Pharmaceuticals

Dechra Veterinary Products EU (DVP EU)

People Cyan Icon



Countries Cyan Icon



DVP EU markets and sells Dechra's products throughout Europe and exports to over 40 countries. The business has an operating board of eight senior managers, and is managed from Den Bosch, the Netherlands, Sansaw, UK, and Uldum, Denmark. In total, DVP EU employs 364 people and maintains an outsourced sales force of 20 people located in different territories. Inventory is managed through a central distribution centre in Uldum, Denmark.

DVP EU has sales operations in 14 countries: Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the UK, each run by a Country Manager. DVP EU also exports to other European countries as well as other territories including Australia, Brazil, the Middle East and the Far East.

The key products in the DVP EU portfolio are predominantly Companion Animal and Equine Products; however, with the acquisition of Eurovet® in 2012, the range expanded into the food producing animal market.

DVP EU also markets a range of specialist, therapeutic and maintenance pet diets, branded Specific.

Dechra Pharmaceuticals Manufacturing (DPM)

People Cyan Icon



Manufacturing Cyan Icon


Manufacturing Sites

DPM produces the majority of Dechra's pharmaceuticals and also manufactures for third parties on a contract basis. The objectives of manufacturing are to produce Dechra's veterinary pharmaceutical product range efficiently and economically to the highest quality standards, maintain a robust and reliable supply chain for the Group and to contribute revenue and profit to the business through third party manufacturing.


The site at Skipton, UK, employs 239 people, and offers a comprehensive range of pharmaceutical manufacturing and packing services, principally for Companion Animal Products (CAP). The site is dual-licensed to produce both veterinary and human products. The site includes Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.


The site at Bladel, the Netherlands, employs 122 people. The operation complements the Skipton site, manufacturing products for food producing animals in large-scale batches. This site also has an aseptic manufacturing facility to produce sterile injections, an important competence in DPM's manufacturing portfolio. As in Skipton, the site includes QC and Development Laboratories.


The site at Melbourne, Florida, employs 13 people. It manufactures Phycox and Levocrine®.

Revenue for the EU Pharmaceuticals Segment

Revenue for EU

Profit Evolution for EU

Profit Evolution

Manufacturing Volumes

manufacturing Volumes

North America Pharmaceuticals

Dechra Veterinary Products North America (DVP NA)

People Cyan Icon



Locations Cyan Icon



DVP NA markets and sells Dechra's veterinary products across Canada (DVP Canada) and the US (DVP US), the latter being the world's largest animal health market.

The US business is strategically located in Kansas City, at the heart of the 'Animal Health Corridor', an area recognised globally for its concentration of animal health businesses. Led by an operating board of four senior managers, DVP US has 61 employees at year end, 47 of whom are field-based sales representatives responsible for around 1,000 clinics each. The rest of the team consists of marketing professionals, in-house veterinarians, field veterinarians, technical support staff and a customer service team.

DVP US currently markets Companion Animal and Equine Products.

DVP Canada was established in January 2015 and currently employs eight people. The office is located in Montreal. DVP Canada markets CAP and Equine products.

Revenue for DVP NA

Revenue for DVP

Profit Evolution for DVP NA

Profit Evolution DVP

Product Development and Regulatory Affairs

People Cyan Icon



Locations Cyan Icon



The Product Development team develops Dechra's own branded veterinary product portfolio of novel and generic pharmaceuticals. The Regulatory Affairs team obtains licences for our products, manages post approval adverse event reporting, periodic product renewals and other activities required to maintain the product licenses.

A total of 62 people at 30 June 2015 work across European Regulatory Affairs, US Regulatory Affairs, Pharmaceutical Development and Product Development. They work at four locations in Overland Park, USA, Sansaw, England, Skipton, England, and Bladel, the Netherlands. The team includes highly qualified academics, veterinarians, formulation chemists, pharmacists, analysts, clinical trial managers and product development managers.

Development Spend

Development Spend